AlphAIAlphAI — Financial news for AI agents
rttnews.com$PDSB

PDS Biotech Raises Up To $22.55M In PIPE Led By Dr. Patrick Soon-Shiong

PDS Biotech (PDSB) raised up to $22.55M in a PIPE transaction led by Nant Capital. The financing includes an initial $11.55M closing and a $11M milestone closing tied to FDA submission. Proceeds will support PDS0301's late-stage development. PDSB stock is up 29.70%.

Original reporting
rttnews.com
Published Sep 8, 2026, 4:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 4:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$PDSB
Bullish
high confidence
Mentioned
$PDSB
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$PDSBBullishHigh
01

Why it matters

The PIPE financing secures needed capital for advancing PDS0301, while interim Phase 2 results show promising survival outcomes, likely prompting investor interest.

02

Market read

The financing and trial data provide fresh catalysts for PDSB, potentially driving short‑term price appreciation and influencing peer biotech sentiment.

03

What to watch

Potential regulatory delays for the Phase 3 filing and execution risk of milestone payments.

Relevance 8/10Novelty 8/10Timing: initial closing expected Sep 11 2026

Background

PDS Biotech is a clinical‑stage company developing IL‑12 immunocytokine therapies for solid tumors.

Company-level read

Ticker impact

$PDSBBullishHigh confidence
Context

PDS Biotech announced a PIPE financing of up to $22.55 million, with an initial $11.55 million closing expected around Sep 11 2026.

Expected impact

Potential short‑term upside of 10‑15% if the financing proceeds and Phase 3 filing are confirmed.

Evidence & confidence

New financing and positive Phase 2 data are fresh catalysts for a micro‑cap biotech, likely attracting speculative buying.

Market effects

Sector

Adds momentum to the oncology immunotherapy sector as a peer secures significant funding.

Regional

May lift other US‑listed biotech stocks in the near term.

Global

Limited to biotech investors; unlikely to affect broader indices.

Counterpoint

What could challenge this read

The modest raise size and dilution risk could outweigh short‑term hype, leading to price pressure.

Key entities

  • company
    PDS Biotechnology Corporation

    US‑listed biotech (NASDAQ:PDSB) developing targeted immunotherapies.

  • investor
    Nant Capital, LLC

    Lead investor in the PIPE transaction.

  • individual
    Dr. Patrick Soon‑Shiong

    Founder of NantWorks and designated board member of PDSB.

Read at source← All news

Also covered by

1 outlet

Related articles

$PDSBHighAI 8/10

B.Riley raises PDS Biotechnology stock price target on trial data

B.Riley raised its price target for PDS Biotechnology (PDSB) to $4.00 from $3.00, maintaining a Buy rating. The stock has gained 97% year-to-date, trading at $1.52. The upgrade follows positive trial data for PDS0301 in liver-metastatic colorectal cancer. PDSB plans to submit a Phase 3 protocol by Q4 2024, with a trial start in Q1 2027. The company also announced leadership changes and a share structure amendment.

investing.com
$PDSBMedAI 8/10

PDS Biotechnology updates corporate presentation highlighting PDS0301 Phase 2 results, near-term data readouts

PDS Biotechnology updated its corporate presentation, reporting strong interim results for PDS0301 in combination with chemotherapy, including a 71.4% objective response rate and median OS exceeding 34 months in a Phase 2 mCRC trial. The company also highlighted upcoming data readouts and a planned Phase 3 protocol for PDS0301, as well as results for PDS0101 in a Phase 2 trial. PDS0101 is seeking partnerships for further development.

tradingview.com
$PDSBMed

PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer

PDS Biotechnology (NASDAQ: PDSB) is planning a Phase III trial for PDS0301 in metastatic colorectal cancer. Early studies showed promising results, with a 70% response rate at six months. The company has discussed the trial design with the FDA and aims to start the trial in early 2027. PDS0301 is being evaluated in combination with hepatic artery infusion pump therapy, which showed durable responses and manageable side effects.

finance.yahoo.com
$PDSBMedAI 8/10

PDSB Jumps As JAMA Data And Nant Capital Deal Reshape The Story

PDS Biotechnology (PDSB) shares rose 13.08% on October 13, 2026, driven by positive clinical data and a financing deal. The company reported a 36% objective response rate in a Phase 2 trial published in JAMA Oncology, outperforming historical benchmarks. PDSB also secured $11.3M in funding from Nant Capital, though at a dilutive price. The stock's recent surge reflects optimism around its immunotherapy pipeline and strategic partnerships, despite its fragile financials.

stockstotrade.com
$PDSBMedAI 8/10

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic…

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune

SEC EDGAR 8-K
$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

rttnews.com